A Prognostic Model for HIV Seroconversion Among Injection Drug Users As a Tool for Stratification in Clinical Trials
Overview
Affiliations
Objective: The main goal of this study was to construct a prognostic model for HIV seroconversion among injection drug users (IDUs) using easy-to-measure risk indicators.
Design: Cox proportional hazards regression modeling was used for risk stratification in a heterogeneous population of IDUs with regards to HIV risk-taking behaviors.
Methods: Subjects were recruited in a prospective cohort of IDUs followed between September 1992 and October 2001. A total of 1602 men, seronegative at enrollment with at least 1 follow-up visit, were included in the analyses. Only variables that consistently predict HIV seroconversion in several settings were considered. The final model was used to assign a risk score for each participant.
Results: Three risk indicators were included in the risk score to predict HIV seroconversion: unstable housing, average cocaine injections per day, and having shared a syringe with a known HIV-positive partner. Kaplan-Meier survival functions were generated and risk score values stratified in 3 groups. HIV incidence rates per 100 person-years were as follows: 0.91 (95% CI, 0.55-1.52) for the low-risk group, 3.10 (95% CI, 2.49-3.84) for the moderate-risk group, and 7.82 (95% CI, 6.30-9.73) for the high-risk group (log-rank P value < 0.0001).
Conclusion: If validated in other settings, this risk score may improve the prediction of outcome and allow more accurate stratification in clinical trials.
Tomescu C, Colon K, Smith P, Taylor M, Azzoni L, Metzger D J Leukoc Biol. 2020; .
PMID: 33289158 PMC: 8244827. DOI: 10.1002/JLB.5A0920-604R.
Real-World Eligibility for HIV Pre-exposure Prophylaxis Among People Who Inject Drugs.
Picard J, Jacka B, Hoj S, Laverdiere E, Cox J, Roy E AIDS Behav. 2020; 24(8):2400-2408.
PMID: 31997057 PMC: 10710293. DOI: 10.1007/s10461-020-02800-w.
Mir M, Akhtar F, Zhang M, Thomas N, Shao H Cureus. 2018; 10(9):e3328.
PMID: 30473961 PMC: 6248663. DOI: 10.7759/cureus.3328.
Colon K, Speicher D, Smith P, Taylor M, Metzger D, Montaner L J Acquir Immune Defic Syndr. 2018; 80(2):234-241.
PMID: 30422902 PMC: 6331283. DOI: 10.1097/QAI.0000000000001911.
Tomescu C, Seaton K, Smith P, Taylor M, Tomaras G, Metzger D J Acquir Immune Defic Syndr. 2014; 68(3):264-73.
PMID: 25514793 PMC: 4329050. DOI: 10.1097/QAI.0000000000000470.